Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for anxiety in children and adolescents with Tourette syndrome
ACTRN12621001659897Phase 3Completed
- Sponsor
- Children's Health Queensland Hospital and Health Service
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Tourette syndrome (TS) and anxiety disorder (2 arms), sponsored by Children's Health Queensland Hospital and Health Service. Primary endpoint: Change in total anxiety score on the Revised Children’s Anxiety and Depression Scale. Started Mar 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
Tourette syndrome (TS)anxiety disorder
Beyond the preview
Go deeper on ACTRN12621001659897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001659897.